ARTICLE
The initial phase connected hospitals, distributors, and advising partners at unprecedented scale to test whether shared visibility can strengthen drug supply resiliency Wilmington, Del. – February 24, 2026 – The End Drug Shortages Alliance (EDSA) today announced the results from the initial phase of its Drug Resiliency & Transparency Pilot, a landmark effort that brought together leading hospitals, distributors, and healthcare advisors to test whether responsible, well-governed data sharing could strengthen drug supply resiliency before shortages occur. Launched through the Cancer Moonshot initiative and led by EDSA, the Pilot brought together seven hospitals, three pharmaceutical distributors, and three national health leaders to share critical inventory data for seven pediatric cancer drugs. Through a purpose-built framework led by EDSA as a neutral, nonprofit convener, participants shared aggregated, non-competitive data across traditional boundaries. Pilot participants include: Hospitals Distributors Advising Partners Children’s Hospital of Philadelphia Children’s Mercy Kansas City Cincinnati Children’s St. Jude Children’s Research Hospital Texas Children’s Hospital Lucile Packard Children's Hospital at Stanford One additional hospital partner Cencora Morris & Dickson McKesson Angels for Change Children’s Hospital Association US Pharmacopeia Results from the initial phase demonstrated both the feasibility and value of this approach: 83% of participants used the shared information for inventory planning. Trustworthiness of the data was identified as the highest value of the Pilot, followed closely by relevance. 100% of participants would participate in future data-sharing efforts. Notably, the medications studied in the Pilot did not have active shortages during data collection, underscoring the value of shared visibility for planning in times of stability, not just crisis response. “Our initial phase showed what is possible when trusted leaders across the supply chain come together around a shared purpose,” said April Giles, Executive Director of EDSA. “By serving as a neutral convener, EDSA created the governance, discipline, and trust necessary for responsible collaboration at scale. The results make clear that transparency can support better planning, stronger stewardship, and a more resilient system overall.” Participants engaged through structured reporting and controlled data distribution , ensuring that insights supported system-level understanding without exposing proprietary or competitively sensitive information. EDSA’s role as data steward and convener was central to establishing the credibility and guardrails that enabled participation by organizations operating at the highest levels of complexity and responsibility. Future phases of the Pilot will focus on expanding participation, increasing automation, and advancing from shared visibility toward coordinated decision enablement while maintaining the governance and trust that made early collaboration possible. The results of the initial phase have been published in an EDSA white paper titled An Unprecedented, System-Level Approach to Resiliency: Insights and Opportunities from the Drug Resiliency & Transparency Pilot.
The initial phase connected hospitals, distributors, and advising partners at unprecedented scale to test whether shared visibility can strengthen drug supply resiliency
Wilmington, Del. – February 24, 2026 – The End Drug Shortages Alliance (EDSA) today announced the results from the initial phase of its Drug Resiliency & Transparency Pilot, a landmark effort that brought together leading hospitals, distributors, and healthcare advisors to test whether responsible, well-governed data sharing could strengthen drug supply resiliency before shortages occur.
Launched through the Cancer Moonshot initiative and led by EDSA, the Pilot brought together seven hospitals, three pharmaceutical distributors, and three national health leaders to share critical inventory data for seven pediatric cancer drugs. Through a purpose-built framework led by EDSA as a neutral, nonprofit convener, participants shared aggregated, non-competitive data across traditional boundaries.
Pilot participants include:
Hospitals
Distributors
Advising Partners
Results from the initial phase demonstrated both the feasibility and value of this approach:
Notably, the medications studied in the Pilot did not have active shortages during data collection, underscoring the value of shared visibility for planning in times of stability, not just crisis response.
“Our initial phase showed what is possible when trusted leaders across the supply chain come together around a shared purpose,” said April Giles, Executive Director of EDSA. “By serving as a neutral convener, EDSA created the governance, discipline, and trust necessary for responsible collaboration at scale. The results make clear that transparency can support better planning, stronger stewardship, and a more resilient system overall.”
Participants engaged through structured reporting and controlled data distribution , ensuring that insights supported system-level understanding without exposing proprietary or competitively sensitive information. EDSA’s role as data steward and convener was central to establishing the credibility and guardrails that enabled participation by organizations operating at the highest levels of complexity and responsibility.
Future phases of the Pilot will focus on expanding participation, increasing automation, and advancing from shared visibility toward coordinated decision enablement while maintaining the governance and trust that made early collaboration possible.
The results of the initial phase have been published in an EDSA white paper titled An Unprecedented, System-Level Approach to Resiliency: Insights and Opportunities from the Drug Resiliency & Transparency Pilot.